Literature DB >> 20531177

Nonalcoholic fatty liver disease in children.

Anna Alisi1, Mattia Locatelli, Valerio Nobili.   

Abstract

PURPOSE OF REVIEW: The intent of this review is to provide a concise overview of all recent acquisitions in terms of therapies and early noninvasive diagnostic approaches for nonalcoholic fatty liver disease (NAFLD) in children. RECENT
FINDINGS: NAFLD is increasingly being diagnosed in children. If undiscovered and if certain risks are present (i.e. obesity), nonalcoholic steatohepatitis, the most severe form of NAFLD, may silently progress to cirrhosis, hepatocarcinoma and liver-related death in adulthood. Current therapies include approaches for reducing the incidence of risk factors (i.e. weight reduction), drugs targeting the major molecular mechanisms thought essential in the pathogenesis of the disease (insulin resistance and oxidative stress) or both, but other novel treatments are under investigation.
SUMMARY: Although weight reduction, achieved through a combination of diet and exercise, makes it possible to modify the natural course of simple steatosis, the addition of adequate drugs might also provide a therapeutic action on nonalcoholic steatohepatitis. Moreover, preventive strategies and the design and translation into clinical practice of indices that integrate noninvasive diagnostic tools and serum biomarkers might be a winning approach for improving management of paediatric NAFLD/nonalcoholic steatohepatitis in the coming years.

Entities:  

Mesh:

Year:  2010        PMID: 20531177     DOI: 10.1097/MCO.0b013e32833aae84

Source DB:  PubMed          Journal:  Curr Opin Clin Nutr Metab Care        ISSN: 1363-1950            Impact factor:   4.294


  14 in total

Review 1.  Obesity, insulin resistance and diabetes: sex differences and role of oestrogen receptors.

Authors:  M R Meyer; D J Clegg; E R Prossnitz; M Barton
Journal:  Acta Physiol (Oxf)       Date:  2011-02-01       Impact factor: 6.311

2.  Nonalcoholic fatty liver disease: Targeted therapy in children--what is the right way?

Authors:  Anna Alisi; Valerio Nobili
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-07-12       Impact factor: 46.802

Review 3.  Effects of physical activity upon the liver.

Authors:  Roy J Shephard; Nathan Johnson
Journal:  Eur J Appl Physiol       Date:  2014-11-04       Impact factor: 3.078

Review 4.  Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach.

Authors:  Anna Alisi; Ariel E Feldstein; Alberto Villani; Massimiliano Raponi; Valerio Nobili
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-01-17       Impact factor: 46.802

5.  Dietary whey protein lowers the risk for metabolic disease in mice fed a high-fat diet.

Authors:  Howard G Shertzer; Sally E Woods; Mansi Krishan; Mary Beth Genter; Kevin J Pearson
Journal:  J Nutr       Date:  2011-02-10       Impact factor: 4.798

6.  Paediatric non-alcoholic Fatty liver disease: impact on patients and mothers' quality of life.

Authors:  Luigi Mazzone; Valentina Postorino; Lavinia De Peppo; Claudia Della Corte; Giuseppe Lofino; Lia Vassena; Laura Fatta; Marco Armando; Giorgio Bedogni; Stefano Vicari; Valerio Nobili
Journal:  Hepat Mon       Date:  2013-03-12       Impact factor: 0.660

7.  Intrauterine growth retardation and nonalcoholic Fatty liver disease in children.

Authors:  Anna Alisi; Nadia Panera; Carlo Agostoni; Valerio Nobili
Journal:  Int J Endocrinol       Date:  2011-11-30       Impact factor: 3.257

Review 8.  Meta-omic platforms to assist in the understanding of NAFLD gut microbiota alterations: tools and applications.

Authors:  Federica Del Chierico; Daniela Gnani; Pamela Vernocchi; Andrea Petrucca; Anna Alisi; Bruno Dallapiccola; Valerio Nobili; Putignani Lorenza
Journal:  Int J Mol Sci       Date:  2014-01-07       Impact factor: 5.923

Review 9.  Role of hepatic progenitor cells in nonalcoholic fatty liver disease development: cellular cross-talks and molecular networks.

Authors:  Guido Carpino; Anastasia Renzi; Paolo Onori; Eugenio Gaudio
Journal:  Int J Mol Sci       Date:  2013-10-09       Impact factor: 5.923

10.  Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease.

Authors:  Anna Alisi; Sara Ceccarelli; Nadia Panera; Federica Prono; Stefania Petrini; Cristiano De Stefanis; Marco Pezzullo; Alberto Tozzi; Alberto Villani; Giorgio Bedogni; Valerio Nobili
Journal:  PLoS One       Date:  2013-06-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.